NapaJen Pharma
Manufacturing · Japan · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Dt 105 2-24-16 Nakacho, Nakacho, Tokyo, ...Phone Number
(650) 685-2429Website
www.napajen.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About NapaJen Pharma
NapaJen Pharma, Inc. is a clinical-stage biopharmaceutical company that utilizes its proprietary immune cell-targeted oligonucleotide delivery technology to create innovative therapeutics. The company addresses the challenges of delivering nucleic acid-based drugs by developing solutions that enhance stability, bioavailability, and cellular uptake. NapaJen Pharma not only focuses on its internal drug development but also collaborates with biotechnology and pharmaceutical companies to advance their oligonucleotide therapeutics. Their unique platform technology significantly accelerates the drug development process, making them a preferred partner in the industry.Explore more
NapaJen Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NapaJen Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when NapaJen Pharma launches new products
Earning: See what the market has to say on NapaJen Pharma recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at NapaJen Pharma
Click to see if NapaJen Pharma had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if NapaJen Pharma has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once NapaJen Pharma has new funding data
Check out if NapaJen Pharma is spiking on competitors!
NapaJen Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined NapaJen Pharma as Masked Content
Find 2 more new buyers
Compare Similar Companies to NapaJen Pharma
Compare insights from companies similar to NapaJen Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NapaJen Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NapaJen Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NapaJen Pharma.
NapaJen Pharma financials insights
Gather financial insights about NapaJen Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$10M
2018
Series B
$15.5M
2019
Series C
$12.4M
NapaJen Pharma Tech Stack
A closer look at the technologies used by NapaJen Pharma
NapaJen Pharma News & Media
NapaJen Pharma and Astellas Pharma Establish Research Collaboration for Discovery and Development of Novel Oligonucleotides
Collaboration to Leverage NapaJen’s Novel Delivery Technology to Overcome Challenges Associated with Delivery of Oligonucleotide-Based Therapies Collaboration to Leverage NapaJen’s Novel Delivery Technology to Overcome Challenges Associated with Delivery of Oligonucleotide-Based Therapies/CORRECTION/ -- NapaJen Pharma, Inc./
TOKYO and BURLINGAME, Calif., Jan. 9, 2019 /PRNewswire/ -- In the news release, "NapaJen Pharma Closes $12.4 Million Series C Financing" issued on 9-Jan-2019 by NapaJen Pharma, Inc. over PR Newswire, we are advised by the company that one of the investors' name was incorrect. "P&D...NapaJen Pharma Closes $12.4M Series C Financing
NapaJen Pharma, Inc., a Burlingame, CA-based biotherapeutics company leveraging its proprietary immune cell-targeted oligonucleotide delivery technology to develop novel immunotherapeutic agents, closed a $12.4m Series C financing. The round was led by the existing investor, INCJ, Ltd., with participation from existing investor Mitsui & Co. Global Investment and newly participating P&D Directions Inc. The funding […] The post NapaJen Pharma Closes $12.4M Series C Financing appeared first on FinSNapaJen Pharma Closes $12.4 Million Series C Financing
TOKYO and BURLINGAME Calif., Jan. 9, 2019 /PRNewswire/ -- NapaJen Pharma, Inc., a biotherapeutics company leveraging its proprietary immune cell-targeted oligonucleotide delivery technology to develop novel immunotherapeutic agents, has announced the closing of a $12.4 million Series C...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NapaJen Pharma
Sign Up For FreeTo access detailed company insights
NapaJen Pharma, Inc. is a clinical-stage biopharmaceutical company that utilizes its proprietary immune cell-targeted oligonucleotide delivery technology to create innovative therapeutics. The company addresses the challenges of delivering nucleic acid-based drugs by developing solutions that enhance stability, bioavailability, and cellular uptake.... Read More
